Trial · NCT05626634
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
NCT05626634, Phase 2, Completed, Longboard Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy. Trials, record NCT05626634. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05626634
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
- NCT number
- NCT05626634
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 41 participants, actual
- Lead sponsor
- Longboard Pharmaceuticals
- Conditions
- Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Interventions
- LP352, bexicaserin
- First posted
- 2022-11-25
- Last updated
- 2025-12-03
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment-emergent Adverse Events | Baseline up to Week 52 | Incidence and severity of treatment-emergent adverse events, including serious adverse events and adverse events leading to study discontinuation and clinically significant changes in vital signs, physical examination endpoints, clinical safety laboratory values and ECGs |
| Primary | Columbia-Suicide Severity Rating Scale (C-SSRS) Response | Baseline up to Week 52 | Type of Suicidal Ideation, Intensity (1 - 5, with 5 being most severe), Suicidal Behavior |
| Primary | Patient Health Questionnaire-9 Total Score and Question 9 Score | Baseline up to Week 52 | Severity Rating Scale: 0 - 27; higher scores indicate greater severity of depressive disorder |
| Secondary | Percent Change from Baseline in Observed Countable Motor Seizure Frequency During the Treatment Period | Baseline to Week 50 | Baseline Used for Seizure Frequency = Baseline from Study LP352-201 and Baseline from Study LP352-202 |
| Secondary | Proportion of Subjects with > 50% Reduction in Total Seizures During the Treatment Period | Baseline to Week 50 | |
| Secondary | Percent Reduction in Individual Seizure Type During the Treatment Period | Baseline to Week 50 | |
| Secondary | Proportion of Subjects Requiring Rescue Medication During the Treatment Period | Baseline to Week 50 | |
| Secondary | Percent Change from Baseline in the Number of Episodes of Status Epilepticus During the Treatment Period | Baseline to Week 50 | |
| Secondary | Percent of Subjects with Countable Motor Seizure-free Days During the Treatment Period | Baseline to Week 50 | |
| Secondary | Percentage Change from Baseline in Non-motor and Difficult to Count Seizures | Baseline to Week 50 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05626634
GET https://conductscience.org/api/trials/v1/NCT05626634/registered